Background PDK1 is an essential protein kinase that plays a critical role in mammalian development. Mouse lacking PDK1 leads to multiple abnormalities and embryonic lethality at E9.5. To elucidate the role of PDK1 in ...Background PDK1 is an essential protein kinase that plays a critical role in mammalian development. Mouse lacking PDK1 leads to multiple abnormalities and embryonic lethality at E9.5. To elucidate the role of PDK1 in the heart, we investigated the cardiac phenotype of mice that lack PDK1 in the heart in different growth periods and the alteration of PDK1 signaling in human failing heart.Methods We employed Cre/loxP system to generate PDK1flox/flox： α-MHC-Cre mice, which specifically deleted PDK1 in cardiac muscle at birth, and tamoxifen-inducible heart-specific PDK1 knockout mice （PDK1flox/flox：MerCreMer mice）, in which PDK1 was deleted in myocardium in response to the treatment with tamoxifen. Transmural myocardial tissues from human failing hearts and normal hearts were sampled from the left ventricular apex to analyze the activity of PDK1/Akt signaling pathways by Western blotting.Results PDK1flox/flox： α-MHC-Cre mice died of heart failure at 5 and 10 weeks old. PDK1flox/flox-MerCreMer mice died of heart failure from 5 to 21 weeks after the initiation of tamoxifen treatment at 8 weeks old. We found that expression levels of PDK1 in human failing heart tissues were significantly decreased compared with control hearts.Conclusion Our results suggest that PDK1 signaling network takes part in regulating cardiac viability and function in mice, and may be also involved in human heart failure disease.展开更多
Deregulation of the phosphatidylinositide 3-kinase(PI3K) and mammalian target of rapamycin(mTOR) signaling pathway occurs frequently in a wide range of human cancers and is a major driving force in tumorigenesis.Thus,...Deregulation of the phosphatidylinositide 3-kinase(PI3K) and mammalian target of rapamycin(mTOR) signaling pathway occurs frequently in a wide range of human cancers and is a major driving force in tumorigenesis.Thus,small molecules targeting this pathway are under active development as anticancer therapeutics.Although small-molecule inhibitors of the PI3K-mTOR pathway have shown promising clinical efficacy against human cancers,the emergence of drug resistance may limit their success in the clinic.To date,several resistance mechanisms,including both PI3K-dependent and-independent mechanisms,have been described.Here,we summarize the current understanding of resistance mechanisms to PI3K-mTOR inhibitors and discuss potential strategies for overcoming resistance for potential clinical application.展开更多
Pyruvate dehydrogenase kinase 1(PDK1)phosphorylates the pyruvate dehydroge-nase complex,which inhibits its activity.Inhibiting pyruvate dehydrogenase complex inhibits the tricarboxylic acid cycle and the reprogramming...Pyruvate dehydrogenase kinase 1(PDK1)phosphorylates the pyruvate dehydroge-nase complex,which inhibits its activity.Inhibiting pyruvate dehydrogenase complex inhibits the tricarboxylic acid cycle and the reprogramming of tumor cell metabolism to glycolysis,which plays an important role in tumor progression.This study aims to elucidate how PDK1 pro-motes breast cancer progression.We found that PDK1 was highly expressed in breast cancer tissues,and PDK1 knockdown reduced the proliferation,migration,and tumorigenicity of breast cancer cells and inhibited the HIF-1α(hypoxia-inducible factor 1α)pathway.Further investigation showed that PDK1 promoted the protein stability of HIF-1αby reducing the level of ubiquitination of HIF-1α.The HIF-1αprotein levels were dependent on PDK1 kinase activity.Furthermore,HIF-1αphosphorylation at serine 451 was detected in wild-type breast cancer cells but not in PDK1 knockout breast cancer cells.The phosphorylation of HIF-1αat Ser 451 stabilized its protein levels by inhibiting the interaction of HIF-1αwith von Hippel-Lindau and prolyl hydroxylase domain.We also found that PDK1 enhanced HIF-1αtranscriptional ac-tivity.In summary,PDK1 enhances HIF-1αprotein stability by phosphorylating HIF-1αat Ser451 and promotes HIF-1αtranscriptional activity by enhancing the binding of HIF-1αto P300.PDK1 and HIF-1αform a positive feedback loop to promote breast cancer progression.展开更多
基金This work was supported by grants from the National Key Basic Research Program of China （No. 2006CB943500）, National Basic Research Program of China （973 Program, No. 2008CB517303） and the National Science Foundation of China （No. 30770893） to YANG Zhong-zhou and LI Xin-li.Acknowledgements： We are grateful to Dr. Dario Alessi at the University of Dundee, UK for providing the PDK1 floxed mice.
文摘Background PDK1 is an essential protein kinase that plays a critical role in mammalian development. Mouse lacking PDK1 leads to multiple abnormalities and embryonic lethality at E9.5. To elucidate the role of PDK1 in the heart, we investigated the cardiac phenotype of mice that lack PDK1 in the heart in different growth periods and the alteration of PDK1 signaling in human failing heart.Methods We employed Cre/loxP system to generate PDK1flox/flox： α-MHC-Cre mice, which specifically deleted PDK1 in cardiac muscle at birth, and tamoxifen-inducible heart-specific PDK1 knockout mice （PDK1flox/flox：MerCreMer mice）, in which PDK1 was deleted in myocardium in response to the treatment with tamoxifen. Transmural myocardial tissues from human failing hearts and normal hearts were sampled from the left ventricular apex to analyze the activity of PDK1/Akt signaling pathways by Western blotting.Results PDK1flox/flox： α-MHC-Cre mice died of heart failure at 5 and 10 weeks old. PDK1flox/flox-MerCreMer mice died of heart failure from 5 to 21 weeks after the initiation of tamoxifen treatment at 8 weeks old. We found that expression levels of PDK1 in human failing heart tissues were significantly decreased compared with control hearts.Conclusion Our results suggest that PDK1 signaling network takes part in regulating cardiac viability and function in mice, and may be also involved in human heart failure disease.
文摘Deregulation of the phosphatidylinositide 3-kinase(PI3K) and mammalian target of rapamycin(mTOR) signaling pathway occurs frequently in a wide range of human cancers and is a major driving force in tumorigenesis.Thus,small molecules targeting this pathway are under active development as anticancer therapeutics.Although small-molecule inhibitors of the PI3K-mTOR pathway have shown promising clinical efficacy against human cancers,the emergence of drug resistance may limit their success in the clinic.To date,several resistance mechanisms,including both PI3K-dependent and-independent mechanisms,have been described.Here,we summarize the current understanding of resistance mechanisms to PI3K-mTOR inhibitors and discuss potential strategies for overcoming resistance for potential clinical application.
基金supported by grants from the National Natural Science Foundation of China(No.82073255)the Foundation of Chongqing Municipal Education Commission(China)(No.HZ2021006).
文摘Pyruvate dehydrogenase kinase 1(PDK1)phosphorylates the pyruvate dehydroge-nase complex,which inhibits its activity.Inhibiting pyruvate dehydrogenase complex inhibits the tricarboxylic acid cycle and the reprogramming of tumor cell metabolism to glycolysis,which plays an important role in tumor progression.This study aims to elucidate how PDK1 pro-motes breast cancer progression.We found that PDK1 was highly expressed in breast cancer tissues,and PDK1 knockdown reduced the proliferation,migration,and tumorigenicity of breast cancer cells and inhibited the HIF-1α(hypoxia-inducible factor 1α)pathway.Further investigation showed that PDK1 promoted the protein stability of HIF-1αby reducing the level of ubiquitination of HIF-1α.The HIF-1αprotein levels were dependent on PDK1 kinase activity.Furthermore,HIF-1αphosphorylation at serine 451 was detected in wild-type breast cancer cells but not in PDK1 knockout breast cancer cells.The phosphorylation of HIF-1αat Ser 451 stabilized its protein levels by inhibiting the interaction of HIF-1αwith von Hippel-Lindau and prolyl hydroxylase domain.We also found that PDK1 enhanced HIF-1αtranscriptional ac-tivity.In summary,PDK1 enhances HIF-1αprotein stability by phosphorylating HIF-1αat Ser451 and promotes HIF-1αtranscriptional activity by enhancing the binding of HIF-1αto P300.PDK1 and HIF-1αform a positive feedback loop to promote breast cancer progression.
